Brian Durie, MD¹, Antje Hoering, PhD^2*, S. Vincent Rajkumar, MD³, Muneer H. Abidi, MD⁴, Joshua Epstein, DSc⁵, Stephen P. Kahanic, MD^6*, Mohan C. Thakuri, MD⁷, Frederic J Reu⁸, Christopher M. Reynolds, MD^9*, Rachael Sexton, MS^10*, Robert Z. Orlowski, Ph.D., M.D.¹¹, Bart Barlogie, MD, PhD⁵ and Angela Dispenzieri, MD¹²

¹International Myeloma Foundation (IMF) and Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA
²SWOG Statistical Center, Seattle, WA
³Division of Hematology, Department of Internal Medicine, The Mayo Clinic, Rochester, MN
⁴Wayne State University/Karmanos Cancer Center, Detroit, MI
⁵Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR
⁶Siouxland Regional Cancer Center, Sanford NCORP of the Northern Central Plains, Sioux City, IA
⁷Southeast Clinical Oncology Research Consortium NCORP, Cancer Care of Western North Carolina, Asheville, NC
⁸Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
⁹Michigan Cancer Research Consortium NCORP, St. Joseph Mercy Hospital, Ann Arbor, MI
¹⁰Cancer Research And Biostatistics, Seattle, WA
¹¹Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
¹²Division of Hematology, Mayo Clinic, Rochester, MN

Meletios A. Dimopoulos¹, Sebastian Grosicki, MD, PhD², Wieslaw W Jedrzejczak, MD PhD^3*, Hareth Nahi^4*, Astrid Gruber, MD, PhD⁴, Markus Hansson^5*, Catriona Byrne, RN^6*, Richard Labotka, MD, MS⁶, Ai-Min Hui, MD, PhD⁶, Zhaoyang Teng, PhD^6* and Norbert Grzasko, MD, PhD^7*

¹National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
²Department of Cancer Prevention, School of Public Health, Silesian Medical University in Katowice, Katowice, Poland
³Hematology and Oncology, Medical University of Warsaw, MTZ Clinical Research, Warsaw, Poland
⁴Haematology Centre, Karolinska University Hospital, Stockholm, Sweden
⁵Department of Hematology, Skåne University Hospital, Lund, Sweden
⁶Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA
⁷Department of Hematology, St John’s Cancer Center & Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland

Pieter Sonneveld, MD, PhD¹, Hans-Juergen Salwender, MD^2*, Bronno Van Der Holt, PhD^3*, Laila el Jarari^4*, Uta Bertsch, MD^5*, Igor W. Blau, MD^6*, Sonja Zweegman^7*, Katja C. Weisel^8*, Edo Vellenga, MD PhD⁹, Michael Pfreundschuh¹⁰, Annemiek Broijl, MD, PhD^1*, Christof Scheid, MD PhD¹¹, Shulamiet Wittebol, MD^12*, Gerard M.J. Bos, MD, PhD¹³, Marjan Stevens-Kroef^14*, Anna Jauch^15*, Anna Potamianou, MD, PhD^16*, Dirk Hose, MD¹⁷, Reinier Raymakers, MD, PhD¹⁸, Marinus Schaafsme^19*, Marie Jose Kersten, MD, PhD²⁰, Marinus van Marwijk Kooy^21*, Ulrich Duehrsen, Prof. Dr. med.²², Hans Walter Lindemann, MD^23*, Peter Brossart, MD²⁴, Pierre Wijermans²⁵, Henk M. Lokhorst²⁶ and Hartmut Goldschmidt, MD²⁷

¹Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
²Asklepios Klinik Altona, Hamburg, Germany
³HOVON Data Center, Erasmus MC Cancer Institute - Clinical Trial Center, Rotterdam, Netherlands
⁴hovon datacenter, erasmus mc cancer institute, rotterdam, Netherlands
⁵department internal medicine, University hospital of Heidelberg, heidelberg, Germany
⁶Internal Medicine, Charité University Medicine Berlin, Berlin, Germany
⁷department of hematology, VUMC university hospital, Amsterdam, Netherlands
⁸Department of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, University Hospital of Tuebingen, Tuebingen, Germany
⁹Department of Hematology, University Medical Center Groningen, Groningen, Netherlands
¹⁰DSHNHL, Homburg, Germany
¹¹Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany
¹²interne geneeskunde, ziekenhuis gelderse vallei, Ede, Netherlands
¹³Dept. of Internal Medicine, University Hospital Maastricht, Maastricht, Netherlands
¹⁴Laboratorium tumor genetica, Radboud Universitair Medisch Centrum, Nijmegen, Netherlands
¹⁵institute of human genetics, university hospital of heidelberg, heidelberg, Netherlands
¹⁶EMEA Medical, Janssen, Athens, Greece
¹⁷Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany
¹⁸department og hematology, University medical center utrecht, utrecht, Netherlands
¹⁹department of hematology, Medisch Spectrum Twente, Enschede, Netherlands
²⁰Hematology, Academic Medical Center, Amsterdam, Netherlands
²¹department of hematology, Isala Clinics, Zwolle, Netherlands
²²Department of Hematology, University Hospital Essen, Essen, Germany
²³Klinik für Hämatologie / Onkologie, Kath. Krankenhaus Hagen gem. GmbH - St.-Marien-Hospital, Hagen, Germany
²⁴Internal Medicine III, Oncology, Hematology and Rheumatology, University Clinic Bonn, Bonn, Germany
²⁵Dept of Hematology, Haga Hospital, The Hague, Netherlands
²⁶Department of Hematology, VU University Medical Center, Amsterdam, Netherlands
²⁷Medical Clinic V, University Clinic of Heidelberg, Heidelberg, Germany

Meletios A. Dimopoulos¹, Sagar Lonial, MD^2,3, Darrell White, MD⁴, Philippe Moreau^5*, Antonio Palumbo, MD⁶, Jesus San Miguel, MD PhD^7*, Ofer Shpilberg, MD, MPH^8*, Kenneth C. Anderson, M.D⁹, Sebastian Grosicki, MD, PhD¹⁰, Ivan Spicka, MD, PhD^11*, Adam Walter-Croneck^12*, Hila Magen-Nativ^13,14*, Maria-Victoria Mateos¹⁵, Andrew Belch¹⁶, Donna Reece¹⁷, Meral Beksac, MD¹⁸, Eric Bleickhardt^19*, Valerie Poulart^20*, Jessica Katz^21*, Anil K. Singhal^22* and Paul G. Richardson²³

¹National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
²Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
³Winship Cancer Institute of Emory University, Department of Hematology and Medical Oncology, Atlanta, GA
⁴QEII Health Science Center and Dalhousie University, Halifax, NS, Canada
⁵University Hospital, Nantes, France
⁶A.O.U. San Giovanni Battista di Torino - Ospedale Molinette, Torino, Italy
⁷Clinical Universidad de Navarra, Pamplona, Spain
⁸Assuta Medical Centers, Tel-Aviv, Israel
⁹Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
¹⁰Silesian Medical University, Katowice, Poland
¹¹Charles University Hospital, Prague, Czech Republic
¹²Medical University of Lublin, Lublin, Poland
¹³Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel
¹⁴Tel Aviv University, Ramat Aviv, Israel
¹⁵University Hospital of Salamanca-IBSAL, Salamanca, Spain
¹⁶Cross Cancer Institute and University of Alberta, Edmonton, AB, Canada
¹⁷Princess Margaret Cancer Centre, Toronto, ON, Canada
¹⁸Ankara University, Ankara, Turkey
¹⁹Bristol-Myers Squibb, Wallingford, CT
²⁰Bristol-Myers Squibb, Braine-l'Alleud, Belgium
²¹Bristol-Myers Squibb, Princeton, NJ
²²AbbVie Biotherapeutics Inc. (ABR), Redwood City, CA
²³Dana-Farber Cancer Institute, Boston, MA

Saad Usmani^1*, Brendan Weiss^2*, Nizar J Bahlis, MD³, Andrew Belch⁴, Sagar Lonial, MD^5,6, Henk Lokhorst⁷, Peter M. Voorhees, MD⁸, Paul G. Richardson⁹, A Kate Sasser^10*, Amy Axel^10*, Huaibao Feng^11*, Clarissa Uhlar^10*, Jianping Wang^10*, Imran Khan^10*, Tahamtan Ahmadi^10* and Hareth Nahi^12*

¹Levine Cancer Institute/Carolinas Healthcare System, Charlotte, NC
²Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
³Tom Baker Cancer Center–University of Calgary, Calgary, AB, Canada
⁴Cross Cancer Institute, Edmonton, AB, Canada
⁵Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
⁶Winship Cancer Institute of Emory University, Department of Hematology and Medical Oncology, Atlanta, GA
⁷Department of Hematology, VU University Medical Center, Amsterdam, Netherlands
⁸Division of Hematology/Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
⁹Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
¹⁰Janssen Research & Development, LLC, Spring House, PA
¹¹Janssen Research & Development, LLC, Raritan, NJ
¹²Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden

Wee-Joo Chng¹, Hartmut Goldschmidt², Meletios A. Dimopoulos³, Philippe Moreau^4*, Douglas Joshua⁵, Antonio Palumbo⁶, Thierry Facon⁷, Heinz Ludwig⁸, Ludek Pour, MD^9*, Ruben Niesvizky¹⁰, Albert Oriol, MD^11*, Laura Rosinol^12*, Aleksandr Suvorov^13*, Gianluca Gaidano¹⁴, Tomas Pika^15*, Katja Weisel^16*, Vesselina Goranova-Marinova^17*, Heidi H. Gillenwater¹⁸, Nehal Mohamed^18*, Shibao Feng^18* and Roman Hájek¹⁹

¹National University Cancer Institute, National University Health System, Singapore and Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
²Heidelberg Medical University, Heidelberg, Germany
³National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
⁴University of Nantes, Nantes, France
⁵Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
⁶University of Torino, Torino, Italy
⁷CHRU Lille Hopital Claude Huriez, Lille, France
⁸Department of Medicine I, Wilhelminenhospital, Wilhelminen Cancer Research Institute, Vienna, Austria
⁹University Hospital Brno, Brno, Czech Republic
¹⁰Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY
¹¹Institut Català d’Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
¹²Hospital Clínic de Barcelona, Barcelona, Spain
¹³First Republican Clinical Hospital of Udmurtia, Izhevsk, Russia
¹⁴Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
¹⁵University Hospital Olomouc, Olomouc, Czech Republic
¹⁶Universitatsklinikum Tubingen, Tubingen, Germany
¹⁷Hematology Clinic University Multiprofile Hospital for Active Treatment, Plovdiv, Bulgaria
¹⁸Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA
¹⁹University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic